Q-omics provides the consensus-scored MPC1L profile across patient tissues and cancer cell-line models. MPC1L expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MPC1L is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MPC1L RNA expression shows 8,059 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, COAD, and TGCT as cancer lineages where MPC1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPC1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPC1L survival associations across molecular data types. MPC1L RNA expression shows survival associations in the most cancer types (14), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPC1L RNA expression–survival associations across cancer types. High MPC1L expression shows unfavorable associations in LUAD, SCLC and PRAD, but favorable associations in UCEC, KIRC and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for MPC1L RNA expression.
This table summarizes MPC1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MPC1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPC1L shows lower tumor expression in PAAD and higher tumor expression in COAD, ESCA, KICH, KIRC and THCA. The COAD box plot shows higher MPC1L RNA expression in tumor versus normal tissue (log2 FC = +0.544, t-test p = .002).
This table shows molecular features associated with MPC1L in patient tissues and cancer cell lines. In patient samples, MPC1L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MPC1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
